Lakefront Biotherapeutics (LKFT) Inventory (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Inventory for 13 consecutive years, with $20.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory fell 48.87% year-over-year to $20.7 million; the TTM figure through Mar 2026 stood at $20.7 million (down 48.87% YoY), while the FY2025 annual figure was $26.2 million, down 52.14% from the prior year.
• Inventory declined to $20.7 million in Q1 2026 per LKFT's latest filing, from $26.2 million in the prior quarter.
• Across five years, Inventory topped out at $87.5 million in Q1 2024 and bottomed at $20.6 million in Q1 2022.
• Historically, Inventory has averaged $49.0 million across 5 years, with a median of $54.0 million in 2022.
• Annual changes were most pronounced in 2023 — Inventory surged 169.11% — and 2025, when it slumped 62.74%.
• Lakefront Biotherapeutics' Inventory stood at $54.0 million in 2022, then soared by 47.41% to $79.6 million in 2023, then tumbled by 31.27% to $54.7 million in 2024, then tumbled by 52.14% to $26.2 million in 2025, then slipped by 20.89% to $20.7 million in 2026.
• Business Quant data shows LKFT's Inventory at $20.7 million in Q1 2026, $26.2 million in Q4 2025, and $26.8 million in Q3 2025.